| Mark T Heise | Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, M.P-M.) Department of Molecular Pharmaceutics and Drug Delivery and LaMontagne Center for Infectious Disease, University of Texas at Austin, Texas (M.A.C.) Eshelman School of Pharmacy (W.C.Z.) and Department of Genetics, University of North Carolina, University of British Columbia and British Columbia Mental Health and Substance Use Services Research Institute, Dalhousie University (K.B.G.) Division of Pediatric Hematology and Oncology, IWK Health Centre (K.B.G.) and Beatrice Hunter Cancer Research Institute (K.B.G.) |
| Mark T Heise | Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, M.P-M.) Department of Molecular Pharmaceutics and Drug Delivery and LaMontagne Center for Infectious Disease, University of Texas at Austin, Texas (M.A.C.) Eshelman School of Pharmacy (W.C.Z.) and Department of Genetics, University of North Carolina, University of British Columbia and British Columbia Mental Health and Substance Use Services Research Institute, Dalhousie University (K.B.G.) Division of Pediatric Hematology and Oncology, IWK Health Centre (K.B.G.) and Beatrice Hunter Cancer Research Institute (K.B.G.) |